Insights Blog
Explore our thought leadership insights, as life science technologies evolve and accelerate.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
DeciBio Q&A
Pharma & Biotech
The Next Frontier of Sensitivity: DeciBio’s Q&A with Stephane Mouradian of Personalis
DeciBio interviews Stephane Mouradian, Senior Vice President of BD & Marketing at Personalis, about the focus of the company moving forward and their highly sensitive NeXT Personal™ assay.
June 24, 2022
DeciBio Q&A
Pharma & Biotech
The Next Frontier of Sensitivity: DeciBio’s Q&A with Stephane Mouradian of Personalis
DeciBio interviews Stephane Mouradian, Senior Vice President of BD & Marketing at Personalis, about the focus of the company moving forward and their highly sensitive NeXT Personal™ assay.
June 24, 2022
MRD Testing
In The Press
Pharma Manufacturing - mRNA boom: A double-edged sword
Did short-term solutions for COVID-19 stifle long-term mRNA success?
June 23, 2022
In The Press
Pharma Manufacturing - mRNA boom: A double-edged sword
Did short-term solutions for COVID-19 stifle long-term mRNA success?
June 23, 2022
No items found.
DeciBio Q&A
Pharma & Biotech
DeciBio’s Peripheral Biomarkers Q&A with Dr. Ofer Sharon of OncoHost
In this Q&A, our experts interviewed Ofer Sharon, MD, MBA, is CEO and co-founder of OncoHost, a host response profiling company in the peripheral biomarkers space.
June 23, 2022
DeciBio Q&A
Pharma & Biotech
DeciBio’s Peripheral Biomarkers Q&A with Dr. Ofer Sharon of OncoHost
In this Q&A, our experts interviewed Ofer Sharon, MD, MBA, is CEO and co-founder of OncoHost, a host response profiling company in the peripheral biomarkers space.
June 23, 2022
Biomarkers
Proteomics Market
Digital Health
DeciBio Q&A
Pharma & Biotech
Next-Generation Programmable mRNA Therapies Post COVID-19 with Jacob Becraft of Strand Therapeutics
New Podcast Episode: DeciBio interviews Jacob Becraft, the CEO and co-founder of Strand Therapeutics.
June 22, 2022
DeciBio Q&A
Pharma & Biotech
Next-Generation Programmable mRNA Therapies Post COVID-19 with Jacob Becraft of Strand Therapeutics
New Podcast Episode: DeciBio interviews Jacob Becraft, the CEO and co-founder of Strand Therapeutics.
June 22, 2022
Next-Generation Therapeutics
Precision Medicine
Infographic
Clinical Diagnostics
The Precision Oncology Landscape Infographic [Updated June 2022]
The precision oncology landscape is getting crowded, with an increasing number of players offering solutions throughout the diagnostic and treatment journey.
June 14, 2022
Infographic
Clinical Diagnostics
The Precision Oncology Landscape Infographic [Updated June 2022]
The precision oncology landscape is getting crowded, with an increasing number of players offering solutions throughout the diagnostic and treatment journey.
June 14, 2022
Clinical Diagnostics
Companion Diagnostics
ctDNA
DeciBio Data Insights
DeciBio Q&A
Clinical Diagnostics
Cell Therapy Trends: ArsenalBio's differentiation strategy and long-term plans with Tarjei Mikkelsen
We had the chance to talk with Tarjei Mikkelsen PhD, CTO at ArsenalBio, a programmable cell therapy company, to get his thoughts on the cell therapy field.
June 13, 2022
DeciBio Q&A
Clinical Diagnostics
Cell Therapy Trends: ArsenalBio's differentiation strategy and long-term plans with Tarjei Mikkelsen
We had the chance to talk with Tarjei Mikkelsen PhD, CTO at ArsenalBio, a programmable cell therapy company, to get his thoughts on the cell therapy field.
June 13, 2022
Cell & Gene Tx
Precision Medicine is evolving at a rapid pace
Discover how we can help
Get in Touch
© DeciBio 2023 | All rights reserved